Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894549 | 0.80 | — | — | |
| SCHEMBL1752754 | 0.78 | ALDH1A1 (0.42) | MEN1MAPTKMT2A | |
| SCHEMBL28177394 | 0.77 | TSHR (0.36) | — | |
| SCHEMBL22216474 | 0.77 | PER2 (0.31) | — | |
| SCHEMBL8302210 | 0.76 | — | — | |
| SCHEMBL9158625 | 0.76 | ADRA1B (0.33) | MAPTCHRM2 | |
| SCHEMBL22323044 | 0.74 | PER2 (0.35) | — | |
| SCHEMBL22216405 | 0.74 | ALDH1A1 (0.35) | HTTMEN1MAPTKMT2ACHRM2 | |
| SCHEMBL25802572 | 0.74 | KMT2A (0.41) | KMT2A | |
| SCHEMBL29119426 | 0.72 | DRD2 (0.50) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-18 | — | — | US | disclosed |
| US-20250011331-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-3892621-B1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-09-18 | — | — | EP | disclosed |
| EP-3921317-B1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| CN-111434662-B | Haloallylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TransThera Sciences (Nanjing), Inc (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3921317-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-12-15 | — | — | EP | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| EP-0188094-B1 | QUINAZOLINE DERIVATIVES AND ANTIHYPERTENSIVE PREPARATIONS CONTAINING SAME AS EFFECTIVE COMPONENTS | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| EP-0192783-B1 | 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4742165-A | HERBICIDES | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| US-4734418-A | Quinazoline compounds and antihypertensives | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| US-4663319-A | LIVER DISORDERS | TANABE SEIYSKU CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0192783-A1 | 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| EP-0188094-A2 | Quinazoline derivatives and antihypertensive preparations containing same as effective components | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
| EP-0149534-A2 | Novel thioketene derivatives and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011331-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | INMT 2695/4885PIK3CD 2012/4885HTT 1147/4885 |
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | INMT 555/4885PIK3CD 4805/4885HTT 80/4885 |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | ADRA1D, ADRA1A, VAPA | INMT 555/4885PIK3CD 4805/4885HTT 80/4885 |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | CSNK1A1, CSNK1G1, CSNK1E | INMT 2968/4885PIK3CD 386/4885HTT 4701/4885 |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | CSNK1A1, CSNK1G1, CSNK1E | INMT 2968/4885PIK3CD 386/4885HTT 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.